Core Insights - AstraZeneca and Ionis Pharmaceuticals have jointly developed Ipupronit Sodium Injection, which has been approved by the National Medical Products Administration for the treatment of adult patients with hereditary transthyretin amyloidosis polyneuropathy (ATTRv-PN) [1] - Ipupronit Sodium is the first and currently the only gene-silencing agent approved for the treatment of ATTRv-PN in China [1] Group 1: Disease Overview - ATTR is caused by the accumulation of misfolded TTR protein produced by the liver, leading to organ damage and failure, with various complications affecting cardiovascular, neurological, and renal health [2] - ATTR has multiple phenotypes, including ATTR-CM (primarily affecting the heart) and ATTRv-PN (primarily affecting the peripheral nervous system), with ATTRv-PN being a debilitating disease that can lead to motor function impairment within five years of diagnosis [2] - The average age of onset for patients in China is 42 years, with a range from 17 to 68 years, and there is a significant delay of 3 to 4 years from symptom onset to diagnosis due to low awareness among the public and healthcare professionals [2] Group 2: Treatment Insights - Ipupronit Sodium is a gene-silencing agent administered once a month, which works by upstream inhibition of TTR protein production, showing potential for treating various types of transthyretin amyloidosis [3] - The approval of Ipupronit Sodium provides new hope for ATTRv-PN patients, as clinical evidence indicates it can halt the progression of neuropathy and significantly improve neurological function and quality of life [3]

10月26日是国际淀粉样变性日。转甲状腺素蛋白淀粉样变性（ATTR）是一类累及多系统的罕见疾病，其患者常被称为"淀粉人"。 专家表示，从发病数据来看，淀粉样变性仍属于罕见病，但报道的病例数量逐渐增多的背后，意味着可能还存在大量的患者未被正确诊断。而从出现症状开 始，转甲状腺素蛋白淀粉样变性多发性神经病的患者平均生存时间一般只有6~12年。任何一次误诊和诊断延迟，对于患者来说都是生存期的缩短，代价直 指生命。 袁云表示，由于淀粉样变性的症状比较分散，单一科室很难全面识别。希望未来能够建立多学科会诊机制，联合神经内科、心内科、消化科、骨科等科室， 同时开通疑似患者快速转诊通道，帮助疑似淀粉样变性的患者缩短诊断时间，提高早期识别和诊断率。 北京大学第一医院罕见病医学中心主任袁云教授。 袁云介绍，转甲状腺素蛋白淀粉样变性分为两种临床表型，转甲状腺素蛋白淀粉样变性多发性神经病（ATTR-PN）主要"困扰神经"，初期可表现为四肢麻 木、肌肉无力、出汗障碍、肠胃功能紊乱等神经症状。转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）主要"攻击心脏"，表现为心衰、水肿、心律失常、 房颤等心脏有关的症状。当出现这些早期信号时，患者 ...